Ascletis Pharma

Company Drug

Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable

Ascletis Pharma Inc. (HKG: 1672) announced the initiation of a US Phase 1 study of...

Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Fineline Cube Aug 31, 2026

Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the...

Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Fineline Cube Jul 16, 2026

Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of...

Others

Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission

Fineline Cube Apr 8, 2026

Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30...

Drug

Ascletis ASC40 Phase III Success in Acne Vulgaris

Fineline Cube Jan 30, 2026

Ascletis Pharma Inc (HKG: 1672) announced positive top‑line results from the open‑label Phase III study (NCT06248008)...

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026

Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in a 13‑week...

Company R&D

Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy

Fineline Cube Jan 22, 2026

Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37, a next‑generation once‑monthly subcutaneous GLP‑1R/GIPR/GCGR triple‑agonist...

Company Drug

Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND

Fineline Cube Dec 1, 2025

Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP‑1R/GIPR/GCGR...

Company Drug

Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity

Fineline Cube Oct 30, 2025

China‑based Ascletis Pharma Inc. (HKG: 1672) announced the selection of ASC36, a once‑monthly subcutaneous injectable...

Company Drug

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD

Fineline Cube Sep 17, 2025

Ascletis Pharma Inc. (HKG: 1672) announced that its Phase Ib multiple‑ascending‑dose (MAD) study of the oral...

Others

Ascletis Pharma Reports Positive Preclinical Results for ASC47 in Obesity Treatment

Fineline Cube Aug 13, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced encouraging efficacy results from preclinical trials of ASC47,...

Company Drug

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30

Fineline Cube Jul 28, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first participants with obesity or overweight...

Company Drug

Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio

Fineline Cube Jul 1, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of...

Company Drug

Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial

Fineline Cube Jun 4, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the Phase III clinical study of its...

Company Drug

Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US

Fineline Cube May 23, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has received approval from the US...

Company Drug

Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment

Fineline Cube May 21, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced the first subject dosing of the ASC47-103 study...

Company Drug

Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment

Fineline Cube Apr 23, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib...

Company Drug

Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss

Fineline Cube Mar 12, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...

R&D

Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study

Fineline Cube Dec 19, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced encouraging results from a study on its...

Company Drug

Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial

Fineline Cube Nov 8, 2024

Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...

Ascletis Pharma

Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission

Ascletis ASC40 Phase III Success in Acne Vulgaris

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy

Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND

Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity

Ascletis Pharma Reports 28‑Day ASC30 Study Results at EASD

Ascletis Pharma Reports Positive Preclinical Results for ASC47 in Obesity Treatment

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30

Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio

Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial

Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US

Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment

Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment

Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss

Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study

Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories